Long-Term Efficacy and Safety of Enzalutamide Monotherapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Report

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F24%3A00079753" target="_blank" >RIV/00209805:_____/24:00079753 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/24:00136136

Výsledek na webu

<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10994655/" target="_blank" >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10994655/</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1159/000538124" target="_blank" >10.1159/000538124</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Long-Term Efficacy and Safety of Enzalutamide Monotherapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Report

Popis výsledku v původním jazyce

INTRODUCTION: Prostate cancer is one of the most common cancers in men. Despite the sharp rise in incidence, mortality is decreasing. ARTA preparations are preferred options for asymptomatic or mildly symptomatic patients with mCRPC. The use of enzalutamide in elderly patients with mCRPC is risky and depends on a number of factors. An increased risk of falls and fractures has been shown. CASE PRESENTATION: We present a case report of an elderly patient with mCRPC treated with enzalutamide with very good long-term tolerance and efficacy. CONCLUSION: Despite the older age, no reduction of therapy was necessary in the patient due to good tolerance. Administration of enzalutamide in full doses resulted in a very good effect of therapy.

Název v anglickém jazyce

Long-Term Efficacy and Safety of Enzalutamide Monotherapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Report

Popis výsledku anglicky

INTRODUCTION: Prostate cancer is one of the most common cancers in men. Despite the sharp rise in incidence, mortality is decreasing. ARTA preparations are preferred options for asymptomatic or mildly symptomatic patients with mCRPC. The use of enzalutamide in elderly patients with mCRPC is risky and depends on a number of factors. An increased risk of falls and fractures has been shown. CASE PRESENTATION: We present a case report of an elderly patient with mCRPC treated with enzalutamide with very good long-term tolerance and efficacy. CONCLUSION: Despite the older age, no reduction of therapy was necessary in the patient due to good tolerance. Administration of enzalutamide in full doses resulted in a very good effect of therapy.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Case Reports in Oncology

ISSN

1662-6575

e-ISSN

1662-6575

Svazek periodika

17

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

6

Strana od-do

537-542

Kód UT WoS článku

001201754100001

EID výsledku v databázi Scopus

2-s2.0-85190552829